EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Fractional curative killing of pyronaridine or artesunate combinations with tafenoquine, 4-aminoquinolines, or azithromycin in a murine malaria-luciferase model

Gayoung Lee, Janessa Sochima Aneke, David J Sullivan iD

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.00247-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Gayoung Lee und 2 weiteren Autor:innen. Beteiligte Einrichtung: W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Antimalarials, Plasmodium berghei, Azithromycin, Malaria. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, Bloomberg Philanthropies.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malaria drug interactions in cytostatic or inhibitory in vitro assays or suppression models in vivo can be different than curative killing interactions. In the pharmacodynamic high parasitemia Plasmodium berghei ANKA-luciferase mouse blood-stage model, we investigated curative interaction analysis of multiple, daily dosed, short half-life, artesunate or single-dose, long half-life, pyronaridine against three single-dose, long half-life, quinolines—chloroquine, amodiaquine, and tafenoquine. Positive or negative parasiticidal activity measured by parasite reduction rate in the days post-treatment correlated nonspecifically to final curative interactions. Tafenoquine/artesunate and pyronaridine/amodiaquine also had fractional combination curative doses of 0.83 and 0.93, with the rest of the interactions closer to neutral at 0.9–1.1. All tested combinations are in the additive drug interaction range. Time to return of initial parasitemia in subcurative regimens was also imprecise for the prediction of cure with combinations. Short blood half-life azithromycin, requiring multiple daily doses, was additive to artesunate or pyronaridine in fractional curative dose combination killing. Murine malaria high parasitemia drug interactions at the curative metric in vivo are a potential benchmark for human studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntimalarialsPlasmodium bergheiAzithromycinMalariaNaphthyridinesAminoquinolinesArtemisininsBenzoxazolesAnimalsArtesunateMiceAmodiaquineChloroquineParasitemiaDrug Therapy, CombinationDisease Models, AnimalFemaleHalf-Life

Stichwörter der Autor:innen

Plasmodiumamodiaquineartemisinin tafenoquineazithromycinchloroquinecombination chemotherapymalariapyronaridine

Substanzen

ArtesunatepyronaridineAntimalarialstafenoquineAzithromycinNaphthyridinesAminoquinolinesAmodiaquineArtemisininsChloroquine

Autor:innen und Institutionen

  • W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

ORCID-Profile: David J Sullivan

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • Bloomberg Philanthropies

Zitieren

APA

Lee, G., Aneke, J. S., & Sullivan, D. J. (2025). Fractional curative killing of pyronaridine or artesunate combinations with tafenoquine, 4-aminoquinolines, or azithromycin in a murine malaria-luciferase model. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00247-25

Vancouver

Lee G, Aneke JS, Sullivan DJ. Fractional curative killing of pyronaridine or artesunate combinations with tafenoquine, 4-aminoquinolines, or azithromycin in a murine malaria-luciferase model. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00247-25

BibTeX
@article{Lee2025,
  author = {Lee, Gayoung and Aneke, Janessa Sochima and Sullivan, David J},
  title = {Fractional curative killing of pyronaridine or artesunate combinations with tafenoquine, 4-aminoquinolines, or azithromycin in a murine malaria-luciferase model},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.00247-25}
}
Kostenlos starten →